Loading
A phase 3 trial testing TAK-928 in non-small-cell lung cancer, now recruiting.
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07217301, led by Takeda with Innovent Biologics (Suzhou), and recruiting on the registry. Official title: A Randomised, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. Planned enrolment is 600 participants (estimated). The study started in 2025-11-26 and primary completion is expected in 2028-11-01. No results have been posted on ClinicalTrials.gov.
Shares Takeda, Non-small-cell lung cancer.
Shares Takeda, Non-small-cell lung cancer.
Shares Takeda, Non-small-cell lung cancer.
Shares Takeda, Non-small-cell lung cancer.
Shares Takeda, Non-small-cell lung cancer.
Shares Takeda, Non-small-cell lung cancer.
Shares Takeda, Non-small-cell lung cancer.